Full Text available on: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486059/pdf/main.pdf
Sundararaj S. Jeremiah a , Kei Miyakawa a , Takeshi Morita a , Yutaro Yamaoka a, b , Akihide Ryo a, * a Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, 236-0004, Japan b Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Kanagawa, 259-1146, Japan article info Article history: Received 4 September 2020 Accepted 8 September 2020 Available online 11 September 2020 Keywords: Silver nanoparticles Colloidal silver SARS-CoV-2 COVID-19
Abstract The pandemic of COVID-19 is spreading unchecked due to the lack of effective antiviral measures. Silver nanoparticles (AgNP) have been studied to possess antiviral properties and are presumed to inhibit SARS-CoV-2. Due to the need for an effective agent against SARS-CoV-2, we evaluated the antiviral effect of AgNPs. We evaluated a plethora of AgNPs of different sizes and concentration and observed that particles of diameter around 10 nm were effective in inhibiting extracellular SARS-CoV-2 at concentrations ranging between 1 and 10 ppm while cytotoxic effect was observed at concentrations of 20 ppm and above. Luciferase-based pseudovirus entry assay revealed that AgNPs potently inhibited viral entry step via disrupting viral integrity. These results indicate that AgNPs are highly potent microbicides against SARS-CoV-2 but should be used with caution due to their cytotoxic effects and their potential to derange environmental ecosystems when improperly disposed.